KalVista director Daniel Soland resigns; Patrick Treanor appointed to board

KalVista Pharmaceuticals, Inc.

Daniel Soland resigned from board and committees effective May 25, 2022; not due to any disagreement with the Company.
Patrick Treanor appointed as Class II director effective May 26, 2022, term expiring at 2024 annual meeting.
Treanor to receive initial option for 17,000 shares, $42,500 annual cash retainer, and annual option for 10,000 shares after one year.
Treanor determined independent under NASDAQ rules; will execute standard indemnification agreement.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Patrick Treanor

Director

KALV · KalVista Pharmaceuticals, Inc.

Effective: 2022-05-26
Filed: May 27, 2022, 7:59 PM ET

On May 26, 2022 upon the recommendation of the Nominating and Governance Committee of the Board, the Board approved the appointment of Patrick Treanor (“ Mr. Treanor ”) to the Board effective immediately, to serve until his successor is duly elected and qualified, or until his death, resignation or removal.

Departed

Daniel Soland

Director

KALV · KalVista Pharmaceuticals, Inc.

Effective: 2022-05-25
Filed: May 27, 2022, 7:59 PM ET

Effective as of May 25, 2022, Daniel Soland resigned from his position on the Board of Directors (the “ Board ”) of KalVista Pharmaceuticals, Inc. (the “ Company ”) and all committees thereof.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Patrick Treanor was appointed as Director at KalVista Pharmaceuticals, Inc..

Action: appointed
Role: Director

Exact text from the filing

On May 26, 2022 upon the recommendation of the Nominating and Governance Committee of the Board, the Board approved the appointment of Patrick Treanor (“ Mr. Treanor ”) to the Board effective immediately, to serve until his successor is duly elected and qualified, or until his death, resignation or removal.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Daniel Soland resigned as Director at KalVista Pharmaceuticals, Inc..

Action: resigned
Role: Director

Exact text from the filing

Effective as of May 25, 2022, Daniel Soland resigned from his position on the Board of Directors (the “ Board ”) of KalVista Pharmaceuticals, Inc. (the “ Company ”) and all committees thereof.

View on SEC.gov

KalVista Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-22-010855

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.